Latest news for Alliance Growers (OTC:ALGWF) Stock

Alliance Growers Corp is a Canada based diversified cannabis company. It principally operates through the four key divisions namely, Cannabis Botany Centre, Strategic Access to Cannabis for Medical Purposes Regulations Investments, Cannabidiol Oil Supply and Distribution, and Research and Development. The company is focused on the development of Cannabis Botany Centres in Canada.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ABNAF

ACRX

ADGO

AJXGF

ALGWF

AMPH

ANDR

AREX

ASCK

ASRT

BCRX

BVTK

CANL

CDXC

CHKDG

CHMJF

CHOOF

CNBX

COCP

CTRA

CTRC

DFFN

DMAN

DOGZ

DPLO

ENBL

ESEA

ESVIF

ETRN

ETSY

EXPE

EZPW

FAMI

FBEC

FFLWF

FLNT

FNRC

FOSL

FRRSF

FTSI

GBLX

GELT

GLOG

HGTXU

HQGE

HSDT

ICNAF

IDEX

INPX

IONKF

JKSM

JROOF

KGJI

MDCN

MENEF

MGTI

MITK

MPLX

NLBIF

NRGMF

NSCO

NTWK

ONTX

ORMP

OSTK

OTTV

OZSC

PACXF

PAGP

PDSB

PRMW

QUIK

RIOFF

RVLV

SDRL

SEEL

SLDB

SWIR

TIGO

TRLFF

TRPX

TUSK

UNIT

Stocks That Hit 52-Week Lows On Tuesday

ALLIANCE GROWERS CORP by Alliance Growers Corp

Alliance Growers Corp

B of A Securities analyst Justin Post upgrades Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) from Neutral to Buy and raises the price target from $187 to $221.

Upgrades

Price Target

Analyst Ratings

B of A Securities Upgrades Expedia Group to Buy, Raises Price Target to $221

Shareholder Firstlight Management Urges Board Of Sotera Health For Sale Of Nelson Labs Subsidiary

PERI

Perion And Experian Team Up To Boost AI-Powered Ad Solutions Across Devices

PLTR

Pray.com And Palantir Join Forces To Enhance Multilingual Faith-Based Content Using Advanced AI Technology

B of A Securities analyst Tazeen Ahmad initiates coverage on KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy rating and announces Price Target of $22.

Initiation

KALV

B of A Securities Initiates Coverage On KalVista Pharma with Buy Rating, Announces Price Target of $22

Rosenblatt analyst Hans Mosesmann maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and maintains $250 price target.

Rosenblatt Maintains Buy on Micron Technology, Maintains $250 Price Target

Beyond the strategic partnership with Sysco, Square also announced new features to help restaurants run their businesses easily and efficiently. These features are currently rolling out to sellers, with full availability in early 2025.

Square Enters New Partnership With Sysco

B of A Securities analyst Saurabh Pant maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and raises the price target from $42 to $48.

B of A Securities Maintains Buy on Baker Hughes, Raises Price Target to $48

Citigroup analyst Paul Lejuez initiates coverage on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Neutral rating and announces Price Target of $65.

ONON

Citigroup Initiates Coverage On On Holding with Neutral Rating, Announces Price Target of $65

Mizuho analyst John Baumgartner maintains Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) with a Outperform and lowers the price target from $28 to $24.

NOMD

Mizuho Maintains Outperform on Nomad Foods, Lowers Price Target to $24

Barry will continue to report to ICON's Chief Executive Officer, Steve Cutler.

Management

ICLR

ICON Appoints Barry Balfe As COO

Citigroup analyst Paul Lejuez initiates coverage on Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy rating and announces Price Target of $65.

Citigroup Initiates Coverage On Academy Sports with Buy Rating, Announces Price Target of $65

<ul>
<li>Oklo and Switch have signed one of the largest corporate power agreements in history, a 12-gigawatts non-binding Master Power Agreement.</li>
<li>This milestone agreement demonstrates a shared commitment to advancing sustainable energy solutions, supporting data center growth, and driving industry-wide decarbonization.</li>
<li>Oklo's Aurora powerhouses will provide reliable, clean energy for Switch's cutting-edge AI, cloud, and enterprise data center infrastructure.</li>
</ul>

OKLO

Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power

Adjusted operating profit is now expected to range between down 4 percent and down 2 percent in constant currency, compared to the previous range of between down 2 percent and flat in constant currency, reflecting higher investment levels.&nbsp;

Guidance

General Mills Revises FY25 Adjusted EPS Outlook Range To Down 3% To Down 1% In Constant Currency, Compared To Previous Range Of Down 1% To Up 1%

Biotech

Health Care

ORKA

Oruka Therapeutics Announced That It Is Expected To Be Added To The Nasdaq Biotechnology Index (NBI), Oruka's Addition Will Become Effective Prior To Market Open On December 23

ABM Sees FY25 Adjusted EPS Outlook Of $3.60-$3.80 Vs. $3.66 Est., Adjusted EBITDA Margin Of 6.3% to 6.5%

Citigroup analyst Steven Zaccone upgrades Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Sell to Buy and raises the price target from $64 to $133.

OLLI

Citigroup Upgrades Ollie's Bargain Outlet to Buy, Raises Price Target to $133

Baird analyst Andrew Wittmann downgrades Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) from Outperform to Neutral and raises the price target from $54 to $58.

Downgrades

Baird Downgrades Fluor to Neutral, Raises Price Target to $58

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

AGIO

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

Needham analyst Laura Martin maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and raises the price target from $6 to $9.

Needham Maintains Buy on Outbrain, Raises Price Target to $9

Alliance Growers

Comments

Alliance Growers

News

Latest news for Alliance Growers (OTC:ALGWF) Stock

Tuesday, November 12, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga